Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet
Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic
Novo Nordisk primarily focuses on the diabetes and obesity markets with medications like Ozempic and Wegovy. Wegovy was recently granted an extended indication from the FDA to treat cardiovascular ...
Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.
Novo Nordisk's $600 billion valuation makes it one of the top healthcare companies in the world. For investors looking for stocks with more upside, upstart Zealand Pharma may fit the bill.
America versus Europe: The big-cap stocks face off
Who is better, the United States of America or the European Union? On the one hand, European citizens are by and large privy to free access to healthcare, though the land of the free is considerabl...
Why Novo Nordisk Stock Was a Winner Today
A research firm added the European pharmaceutical sector star to its focus list. It was among four stocks earning this status.
What Makes Novo Nordisk (NVO) a Strong Momentum Stock: Buy Now?
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About Novo Nordisk (NVO) Rating Upgrade to Buy
Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Novo Nordisk-owner to expand in India this year
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to open an office in India this year to tap innovation and a growing healthcare market, its CEO Kasim Kut...
Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) an...
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
Novo Nordisk is one of the leading developers of weight-loss drugs. It just shared some great early-stage clinical trial data from one of its programs.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Novo Nordisk (NVO) concluded the recent trading session at $131.24, signifying a -1.38% move from its prior day's close.
Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk
Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
Shares of Novo Nordisk recently rose to a new all-time high in response to clinical trial results for an experimental new weight-management drug named amycretin. Amycretin is a potential first-in-c...
Weight-loss drug Wegovy approved by FDA to cut heart attack, stroke risk
The move confirms that the new class of obesity medications are useful for improving health, not just losing weight.
Related Companies